



SINOWAY Newsletter

January, 2026

★ Market Information

Holiday & Logistics Notice: Chinese Spring Festival & Two Sessions (2026)

- **Chinese Spring Festival** Official holidays: Feb 15 – Feb 23, 2026 Factories, warehouses and most logistics will stop beforehand 1 or 2 weeks before the holidays.
- **Two Sessions (National Meetings)** – Early March 2026 NPC & CPPCC held in Beijing starting March 4–5, lasting ~7–10 days. Expect heightened security in Beijing area: temporary traffic restrictions, stricter inspections, and short delays in domestic trucking, courier, and freight (especially to/from/through northern China).

Impact & Advice Combined Spring Festival + Two Sessions period may cause production slowdowns and logistics delays in Feb–March. To avoid disruptions, we recommend placing orders and scheduling shipments earlier than usual.

Feel free to contact us to reserve production slots or plan shipments ahead—we're here to help ensure smooth delivery.

★ New Product Introduction

Urolithin A (CAS No. 1143-70-0) is an emerging high-value functional ingredient attracting strong interest in the healthy aging, mitochondrial health, and sports nutrition markets. As global demand continues to grow, the market is increasingly focused on **quality consistency, safety control, cost competitiveness, and scalable stable supply**.

Market background:

Historically, the global supply of Urolithin A was largely dominated by Indian manufacturers due to earlier process maturity and cost advantages. Over the past two years, however, **significant technological breakthroughs by Chinese manufacturers** have reshaped the supply landscape. With optimized synthesis and purification processes, Chinese production has achieved **lower manufacturing costs, improved stability, and reliable large-scale output**, making UA more commercially accessible than before.

SINOWAY'S Advantages of Urolithin A:

1. High Purity & Stable Quality

- **Purity:** ≥98% (HPLC) Typical result: 99.7%
- **Appearance:** White to light yellow powder
- **Microbiological profile:** Salmonella, Staphylococcus aureus, Molds & Yeasts **all ND**
- **Batch-to-batch consistency:** Suitable for long-term projects

2. Strict Heavy Metal Control (Key for High-Dosage Products) As Urolithin A is commonly formulated at **relatively high daily dosages**, heavy metal management is a critical quality



factor for finished product safety.

Based on our Certificate of Analysis, our UA shows **excellent heavy metal control**:

- **Lead (Pb): < 0.5 ppm**
- **Arsenic (As): < 0.5 ppm**
- **Cadmium (Cd): < 0.5 ppm**
- **Mercury (Hg): < 0.05 ppm**
- **Copper : < 1.5 ppm**

3. Manufacturing & Supply Advantages

- **Cost Competitiveness:**
Optimized process enables **pricing advantages compared with traditional Indian supply**, without compromising quality.
- **Large-Scale Capacity:**
Annual production capacity of **10 metric tons (easy upscale to 50 ton/year)** , suitable for **commercial-scale programs and long-term supply agreements**.

4. Conclusion :

With improved cost structure, scalable capacity, and strict quality control, **Urolithin A is transitioning from a niche ingredient to a commercially viable functional raw material**.

We are pleased to offer a **competitive, stable, and large-scale Urolithin A supply solution** to support your product development and market expansion plans.

For **samples, specifications, or commercial discussions**, please feel free to contact us.

☆ **One-stop CDMO Solutions for Key intermediates&API&FDF**

One-Stop CDMO Solutions for GLP-1 Therapies: From API to Finished Drug Product

We offer one-stop CDMO services for GLP-1 therapies, spanning from API to finished drug product. Our platform covers peptide API process development and cGMP manufacturing, through formulation development (including Lyophilization Technology), aseptic fill-finish, and packaging. The integrated solution ensures seamless tech transfer and end-to-end quality control, helping partners streamline the supply chain, mitigate risks, and accelerate timelines to efficiently bring innovative GLP-1 drugs to the global market.